Ovid Therapeutics (OVID) Financials

$2.74

$0.05 (1.86%)

As on 14-Sep-2026 16:16EDT

Market cap

$525 Mln

Revenue (TTM)

$2 Mln

P/E Ratio

--

P/B Ratio

2.5

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	1.58	7.25	0.57	0.39	1.50	208.38
Cost of Revenue	0.11	0.30	0.60	1.60	1.38	--
Gross Profit	1.55	6.95	0.57	0.39	1.50	208.38
Operating Expenses	59.94	49.39	62.45	59.67	57.05	84.17
Operating Profit (EBIT)	-58.36	-42.44	-61.89	-59.28	-55.55	124.21
Other Income	--	--	--	--	1.38	--
Profit before Tax	-34.49	-17.41	-26.43	-52.34	-54.17	124.16
Provision for Tax	--	--	--	0.00	-2.76	1.33
Profit after Tax (Net Income)	-34.49	-17.41	-26.43	-52.34	-51.41	122.83
Minority Interest	--	--	--	--	--	--
Consolidated Profit	--	--	--	--	-54.17	119.84

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	209.89	130.66	68.23	87.80	132.27	179.75
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	12.10	11.99	13.42	44.76	16.00	7.13
Current Liabilities	9.98	8.29	10.52	11.47	6.99	14.80
Total Liabilities	241.95	150.93	92.17	144.03	155.27	194.54

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	108.36	60.49	36.23	34.43	23.89	4.07
Current Assets	123.62	90.45	55.94	109.60	131.38	190.48
Total Assets	241.95	150.93	92.17	144.03	155.27	194.54
Total Debt*	12.72	13.42	14.76	16.00	16.54	--
Net Current Assets	113.64	66.08	45.42	98.12	124.39	175.68

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-38.33	-55.96	-45.78	-55.23	118.61
Cash Flow from Investing Activities	--	-49.85	54.59	-2.58	-87.88	-1.82
Cash from Financing Activities	--	75.21	0.62	30.54	0.18	0.90
Net Cash Inflow / Outflow	--	--	--	--	-142.93	117.69

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.49	-0.21	-0.37	-0.74	-0.73	1.80
Cash EPS ($)	-0.21	-0.21	-0.36	-0.72	-0.71	1.81
Adjusted Book Value ($)	1.14	1.60	0.96	1.24	1.88	2.64
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.47	-0.79	-0.65	-0.78	1.74
Free Cash Flow per Share ($)	--	-0.47	-0.79	-0.65	-0.80	1.74

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-15.34	-28.30	-41.44	-31.29	109.98
ROE (%)	-20.26	-17.51	-33.88	-47.57	-32.95	109.98
ROA (%)	-21.01	-14.33	-22.38	-34.98	-29.39	90.83
EBIT Margin (%)	-2,257.68	-240.13	-10,315.37	-14,689.03	-3,696.44	59.61
Net Margin (%)	-2,178.90	-240.13	-4,670.14	-13,351.79	-1,783.85	58.95
Cash Profit Margin (%)	-0.03	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	-76.20	11.81	0.44	-0.74	-0.99	15.52
EBIT Growth (%)	10.31	70.17	-1.40	-3.66	-144.72	252.53
Net Profit Growth (%)	9.65	34.12	49.50	-1.81	-141.85	252.16
EPS Growth (%)	9.48	0.43	0.50	-0.02	-1.40	2.43
Book Value Growth (%)	262.82	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-7.64	-2.51	-4.35	-2.55	1.78
Price / Book Value	2.46	1.02	0.97	2.59	0.99	1.22
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.69	-4.49	-0.48	-2.42	-0.34	0.25
Close Price ($)	2.69	1.63	0.93	3.22	1.86	3.21
High Price ($)	3.11	2.01	4.10	4.14	3.55	4.80
Low Price ($)	0.31	0.24	0.68	1.79	1.41	2.27
Market Cap ($ Cr)	525.35	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.10	0.22	0.18	0.13	--
Short term debt to equity ratio	0.01	0.01	0.02	0.01	0.00	--
Current Ratio	12.39	10.91	5.32	9.55	18.79	12.87
Quick Ratio	12.39	--	--	--	--	--
Interest Coverage	--	--	--	--	-20.12	2,654.40

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	17.38	--
Asset Turnover	0.01	0.06	0.00	0.00	0.01	1.54
Receivable days	--	--	--	243.37	63.48	0.25
Inventory Days	--	--	--	--	--	--
Payable days	--	3,133.24	2,098.36	646.78	1,200.22	--
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.